{"id":999258,"date":"2026-08-31T20:11:07","date_gmt":"2026-09-01T00:11:07","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/an2-therapeutics-presents-clinical-and-translational-data-supporting-development-of-epetraborole-for-polycythemia-vera-at-the-society-of-hematologic-oncology-soho-2026-annual-meeting\/"},"modified":"2026-08-31T20:11:07","modified_gmt":"2026-09-01T00:11:07","slug":"an2-therapeutics-presents-clinical-and-translational-data-supporting-development-of-epetraborole-for-polycythemia-vera-at-the-society-of-hematologic-oncology-soho-2026-annual-meeting","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/an2-therapeutics-presents-clinical-and-translational-data-supporting-development-of-epetraborole-for-polycythemia-vera-at-the-society-of-hematologic-oncology-soho-2026-annual-meeting\/","title":{"rendered":"AN2 Therapeutics Presents Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwblockalignl { margin-left: 0px; margin-right: auto }\n.bwcellpmargin { margin-bottom: 0px; margin-top: 0px }\n.bwleftsingle { border-left: solid black 1pt }\n.bwlistdisc { list-style-type: disc }\n.bwpadl0 { padding-left: 0px }\n.bwpadl1 { padding-left: 5px }\n.bwrightsingle { border-right: solid black 1pt }\n.bwsinglebottom { border-bottom: solid black 1pt }\n.bwtablemarginb { margin-bottom: 10px }\n.bwtopsingle { border-top: solid black 1pt }\n.bwuline { text-decoration: underline }\n.bwvertalignt { vertical-align: top }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>AN2 Therapeutics Presents Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting<\/b><\/p>\n<p class=\"bwalignc\"><i>Abstracts highlight epetraborole\u2019s potential beneficial effects on hematological profile across clinical and nonclinical studies<\/i><\/p>\n<p>MENLO PARK, Calif.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nAN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry platform, today announced that four abstracts highlighting clinical and nonclinical data supporting the development of epetraborole, a novel boron-containing oral candidate for the treatment of polycythemia vera (PV), will be presented at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting, taking place September 9-12, 2026, at the George R. Brown Convention Center in Houston, Texas.<\/p>\n<p>\n&#8220;These abstracts provide insights into the potential beneficial hematological effects of epetraborole across both clinical and nonclinical studies and strengthen our understanding of the exposure-response relationships that we believe support its development in polycythemia vera,&#8221; said George H. Talbot, M.D. Co-Founder and Senior Medical Advisor of AN2 Therapeutics.<\/p>\n<p><b>Key Highlights:<\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li>\nClinical and nonclinical studies demonstrated potential beneficial effects of epetraborole on erythropoiesis and hemoglobin-related parameters.<\/p>\n<\/li>\n<li>\nData further characterized the hematological and safety profile of epetraborole across healthy volunteers, non-PV patients, and nonhuman primate models.<\/p>\n<\/li>\n<li>\nExposure-response relationships observed in nonhuman primates were predictive of effects subsequently observed in humans, supporting the translational relevance of these models.<\/p>\n<\/li>\n<li>\nCollectively, the findings support the ongoing clinical development of epetraborole as a potential oral treatment for PV.<\/p>\n<\/li>\n<\/ul>\n<p><b>SOHO 2026 Abstracts:<\/b><\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl\">\n<tr>\n<td class=\"bwvertalignt bwtopsingle bwsinglebottom bwleftsingle bwrightsingle bwpadl0\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\"><b>Poster Number<\/b><\/p>\n<\/td>\n<td class=\"bwvertalignt bwtopsingle bwsinglebottom bwrightsingle bwpadl0\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\"><b>Title<\/b><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\"><b>MPN-1041<\/b><\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\"><i>Epetraborole Demonstrates an Exposure-Dependent Effect on Erythropoiesis in Healthy Subjects<\/i><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\"><b>MPN-1076<\/b><\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\"><i>Hematological and Safety Profile of Epetraborole in a Non-Polycythemia Vera Patient Population<\/i><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\"><b>MPN-1082<\/b><\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\"><i>Exposure-Response Analyses of Hemoglobin Changes During Epetraborole Administration to Nonhuman Primates Predict Human Exposure-Response Relationships<\/i><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\"><b>MPN-1106<\/b><\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\"><i>Hematological Profile in Nonhuman Primates of Epetraborole, a Novel Boron-Containing Candidate for Oral Treatment of Polycythemia Vera<\/i><\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p>\nCopies of the abstracts will be available on the Presentations and Publications section of the AN2 Therapeutics website at the following link: <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.an2therapeutics.com%2Fpipeline%2F%23presentations&amp;esheet=54596421&amp;newsitemid=20260831566807&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.an2therapeutics.com%2Fpipeline%2F%23presentations&amp;index=1&amp;md5=cd4ed30b606fedce7ed33070d2c84fa2\">https:\/\/www.an2therapeutics.com\/pipeline\/#presentations<\/a><\/p>\n<p><b>About AN2 Therapeutics<\/b><\/p>\n<p>\nAN2 Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the discovery and development of novel small-molecule therapeutics derived from our boron chemistry platform. Our development pipeline spans hematologic diseases, infectious diseases, and oncology with three Phase 2 studies expected to be active in 2026, two preclinical candidates, as well as advanced research programs focused on targets in oncology, bone disorders, and infectious diseases. We are committed to delivering high-impact drugs to patients that address critical unmet needs and improve health outcomes. For more information, please visit our website at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.an2therapeutics.com&amp;esheet=54596421&amp;newsitemid=20260831566807&amp;lan=en-US&amp;anchor=www.an2therapeutics.com&amp;index=2&amp;md5=9a45dfa984fec4346cbafa57aedde620\">www.an2therapeutics.com<\/a>.<\/p>\n<p><b>Forward-Looking Statements<\/b><\/p>\n<p>\nThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by terms such as \u201cmay,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201cwould,\u201d \u201cexpect,\u201d \u201cplan,\u201d \u201canticipate,\u201d \u201ccould,\u201d \u201cintend,\u201d \u201ctarget,\u201d \u201cproject,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cpredict,\u201d \u201cpotential,\u201d or \u201ccontinue,\u201d or the negative of these terms or other similar expressions. Forward-looking statements expressed or implied in this press release include, but are not limited to, statements regarding: preclinical and clinical support for the continued development of epetraborole as a potential oral treatment for PV; potential beneficial hematological effects of epetraborole; the hematological and safety profile of epetraborole; the translational relevance of nonhuman primate studies to human studies; the potential of the Company\u2019s boron chemistry platform and advancement of the Company\u2019s development programs; and other statements that are not historical fact. These statements are based on AN2\u2019s current estimates, expectations, plans, objectives, and intentions, are not guarantees of future performance, and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, but are not limited to, risks and uncertainties related to: AN2\u2019s ability to implement its plans for its internal boron chemistry platform and pipeline programs; timely enrollment of patients in AN2\u2019s clinical trials and investigator-initiated clinical trials; AN2\u2019s ability to procure sufficient supply of its product candidates for its clinical trials; the potential for results from clinical trials to differ from preclinical, early clinical, preliminary, or expected results; the ability of particular preclinical models in non-human primates to predict safety and efficacy in humans; significant adverse events, toxicities, or other undesirable side effects associated with AN2\u2019s product candidates; the significant uncertainty associated with AN2\u2019s product candidates ever receiving any regulatory approvals; AN2\u2019s ability to obtain, maintain, or protect intellectual property rights related to its current and future product candidates; implementation of AN2\u2019s strategic plans for its business and product candidates; the sufficiency of AN2\u2019s capital resources and need for additional capital to achieve its goals; global macroeconomic conditions and global conflicts and other risks, including those described under the heading \u201cRisk Factors\u201d in AN2\u2019s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other reports filed with the U.S. Securities and Exchange Commission (SEC). These filings, when made, are available on the investor relations section of AN2\u2019s website at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.an2therapeutics.com&amp;esheet=54596421&amp;newsitemid=20260831566807&amp;lan=en-US&amp;anchor=www.an2therapeutics.com&amp;index=3&amp;md5=36f0aa47eeae68c0d307a49b3b156bd5\">www.an2therapeutics.com<\/a> and on the SEC\u2019s website at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.sec.gov&amp;esheet=54596421&amp;newsitemid=20260831566807&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=4&amp;md5=c9560c8c4e9156e8924b623f3f59b775\">www.sec.gov<\/a>. Forward-looking statements contained in this press release are made as of this date, and AN2 undertakes no duty to update such information except as required under applicable law.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260831566807r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20260831566807\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20260831566807\/en\/<\/a><\/span><\/p>\n<p><b>Company Contact:<br \/>\n<\/b><br \/>Lucy O. Day<br \/>\n<br \/>Chief Financial Officer<br \/>\n<br \/><span class=\"bwuline\"><a rel=\"nofollow\" href=\"mailto:l.day@an2therapeutics.com\">l.day@an2therapeutics.com<\/a><\/span><\/p>\n<p><b>Investor and Media Contact:<br \/>\n<\/b><br \/>Anne Bowdidge<br \/>\n<br \/><span class=\"bwuline\"><a rel=\"nofollow\" href=\"mailto:ir@an2therapeutics.com\">ir@an2therapeutics.com<\/a><\/span><\/p>\n<p><b>KEYWORDS:<\/b> California Texas United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Biotechnology Pharmaceutical Health Clinical Trials<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260831566807\/en\/1863965\/3\/AN2_Therapeutics_Press_Release_Logo.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>AN2 Therapeutics Presents Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting Abstracts highlight epetraborole\u2019s potential beneficial effects on hematological profile across clinical and nonclinical studies MENLO PARK, Calif.&#8211;(BUSINESS WIRE)&#8211; AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry platform, today announced that four abstracts highlighting clinical and nonclinical data supporting the development of epetraborole, a novel boron-containing oral candidate for the treatment of polycythemia vera (PV), will be presented at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting, taking place September 9-12, 2026, at the George R. Brown Convention &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/an2-therapeutics-presents-clinical-and-translational-data-supporting-development-of-epetraborole-for-polycythemia-vera-at-the-society-of-hematologic-oncology-soho-2026-annual-meeting\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;AN2 Therapeutics Presents Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-999258","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>AN2 Therapeutics Presents Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/an2-therapeutics-presents-clinical-and-translational-data-supporting-development-of-epetraborole-for-polycythemia-vera-at-the-society-of-hematologic-oncology-soho-2026-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AN2 Therapeutics Presents Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"AN2 Therapeutics Presents Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting Abstracts highlight epetraborole\u2019s potential beneficial effects on hematological profile across clinical and nonclinical studies MENLO PARK, Calif.&#8211;(BUSINESS WIRE)&#8211; AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry platform, today announced that four abstracts highlighting clinical and nonclinical data supporting the development of epetraborole, a novel boron-containing oral candidate for the treatment of polycythemia vera (PV), will be presented at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting, taking place September 9-12, 2026, at the George R. Brown Convention &hellip; Continue reading &quot;AN2 Therapeutics Presents Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/an2-therapeutics-presents-clinical-and-translational-data-supporting-development-of-epetraborole-for-polycythemia-vera-at-the-society-of-hematologic-oncology-soho-2026-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-01T00:11:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260831566807r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/an2-therapeutics-presents-clinical-and-translational-data-supporting-development-of-epetraborole-for-polycythemia-vera-at-the-society-of-hematologic-oncology-soho-2026-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/an2-therapeutics-presents-clinical-and-translational-data-supporting-development-of-epetraborole-for-polycythemia-vera-at-the-society-of-hematologic-oncology-soho-2026-annual-meeting\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"AN2 Therapeutics Presents Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting\",\"datePublished\":\"2026-09-01T00:11:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/an2-therapeutics-presents-clinical-and-translational-data-supporting-development-of-epetraborole-for-polycythemia-vera-at-the-society-of-hematologic-oncology-soho-2026-annual-meeting\\\/\"},\"wordCount\":969,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/an2-therapeutics-presents-clinical-and-translational-data-supporting-development-of-epetraborole-for-polycythemia-vera-at-the-society-of-hematologic-oncology-soho-2026-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260831566807r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/an2-therapeutics-presents-clinical-and-translational-data-supporting-development-of-epetraborole-for-polycythemia-vera-at-the-society-of-hematologic-oncology-soho-2026-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/an2-therapeutics-presents-clinical-and-translational-data-supporting-development-of-epetraborole-for-polycythemia-vera-at-the-society-of-hematologic-oncology-soho-2026-annual-meeting\\\/\",\"name\":\"AN2 Therapeutics Presents Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/an2-therapeutics-presents-clinical-and-translational-data-supporting-development-of-epetraborole-for-polycythemia-vera-at-the-society-of-hematologic-oncology-soho-2026-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/an2-therapeutics-presents-clinical-and-translational-data-supporting-development-of-epetraborole-for-polycythemia-vera-at-the-society-of-hematologic-oncology-soho-2026-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260831566807r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2026-09-01T00:11:07+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/an2-therapeutics-presents-clinical-and-translational-data-supporting-development-of-epetraborole-for-polycythemia-vera-at-the-society-of-hematologic-oncology-soho-2026-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/an2-therapeutics-presents-clinical-and-translational-data-supporting-development-of-epetraborole-for-polycythemia-vera-at-the-society-of-hematologic-oncology-soho-2026-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/an2-therapeutics-presents-clinical-and-translational-data-supporting-development-of-epetraborole-for-polycythemia-vera-at-the-society-of-hematologic-oncology-soho-2026-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260831566807r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260831566807r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/an2-therapeutics-presents-clinical-and-translational-data-supporting-development-of-epetraborole-for-polycythemia-vera-at-the-society-of-hematologic-oncology-soho-2026-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AN2 Therapeutics Presents Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AN2 Therapeutics Presents Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/an2-therapeutics-presents-clinical-and-translational-data-supporting-development-of-epetraborole-for-polycythemia-vera-at-the-society-of-hematologic-oncology-soho-2026-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"AN2 Therapeutics Presents Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting - Market Newsdesk","og_description":"AN2 Therapeutics Presents Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting Abstracts highlight epetraborole\u2019s potential beneficial effects on hematological profile across clinical and nonclinical studies MENLO PARK, Calif.&#8211;(BUSINESS WIRE)&#8211; AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry platform, today announced that four abstracts highlighting clinical and nonclinical data supporting the development of epetraborole, a novel boron-containing oral candidate for the treatment of polycythemia vera (PV), will be presented at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting, taking place September 9-12, 2026, at the George R. Brown Convention &hellip; Continue reading \"AN2 Therapeutics Presents Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/an2-therapeutics-presents-clinical-and-translational-data-supporting-development-of-epetraborole-for-polycythemia-vera-at-the-society-of-hematologic-oncology-soho-2026-annual-meeting\/","og_site_name":"Market Newsdesk","article_published_time":"2026-09-01T00:11:07+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260831566807r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/an2-therapeutics-presents-clinical-and-translational-data-supporting-development-of-epetraborole-for-polycythemia-vera-at-the-society-of-hematologic-oncology-soho-2026-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/an2-therapeutics-presents-clinical-and-translational-data-supporting-development-of-epetraborole-for-polycythemia-vera-at-the-society-of-hematologic-oncology-soho-2026-annual-meeting\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"AN2 Therapeutics Presents Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting","datePublished":"2026-09-01T00:11:07+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/an2-therapeutics-presents-clinical-and-translational-data-supporting-development-of-epetraborole-for-polycythemia-vera-at-the-society-of-hematologic-oncology-soho-2026-annual-meeting\/"},"wordCount":969,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/an2-therapeutics-presents-clinical-and-translational-data-supporting-development-of-epetraborole-for-polycythemia-vera-at-the-society-of-hematologic-oncology-soho-2026-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260831566807r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/an2-therapeutics-presents-clinical-and-translational-data-supporting-development-of-epetraborole-for-polycythemia-vera-at-the-society-of-hematologic-oncology-soho-2026-annual-meeting\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/an2-therapeutics-presents-clinical-and-translational-data-supporting-development-of-epetraborole-for-polycythemia-vera-at-the-society-of-hematologic-oncology-soho-2026-annual-meeting\/","name":"AN2 Therapeutics Presents Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/an2-therapeutics-presents-clinical-and-translational-data-supporting-development-of-epetraborole-for-polycythemia-vera-at-the-society-of-hematologic-oncology-soho-2026-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/an2-therapeutics-presents-clinical-and-translational-data-supporting-development-of-epetraborole-for-polycythemia-vera-at-the-society-of-hematologic-oncology-soho-2026-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260831566807r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2026-09-01T00:11:07+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/an2-therapeutics-presents-clinical-and-translational-data-supporting-development-of-epetraborole-for-polycythemia-vera-at-the-society-of-hematologic-oncology-soho-2026-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/an2-therapeutics-presents-clinical-and-translational-data-supporting-development-of-epetraborole-for-polycythemia-vera-at-the-society-of-hematologic-oncology-soho-2026-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/an2-therapeutics-presents-clinical-and-translational-data-supporting-development-of-epetraborole-for-polycythemia-vera-at-the-society-of-hematologic-oncology-soho-2026-annual-meeting\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260831566807r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260831566807r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/an2-therapeutics-presents-clinical-and-translational-data-supporting-development-of-epetraborole-for-polycythemia-vera-at-the-society-of-hematologic-oncology-soho-2026-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"AN2 Therapeutics Presents Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/999258","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=999258"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/999258\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=999258"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=999258"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=999258"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}